Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biondvax Pharma ADR
(NQ:
BVXV
)
1.360
UNCHANGED
Last Price
Updated: 3:59 PM EDT, Sep 6, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biondvax Pharma ADR
< Previous
1
2
3
4
5
Next >
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Innovative Inhaled COVID-19 NanoAb Therapy Shows Statistically Significant Efficacy Results in Preclinical Study
December 13, 2022
Via
Investor Brand Network
Exposures
COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Regains Compliance with Nasdaq Listing Rules
December 12, 2022
Via
Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Investment Research Report
December 09, 2022
Via
Investor Brand Network
Exposures
COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is ‘One to Watch’
November 07, 2022
Via
Investor Brand Network
Teens Suffering from Concussions Could Benefit from Screen Time
December 06, 2022
Via
Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Names Experienced Researcher as Advisory Board Member
December 06, 2022
Via
Investor Brand Network
Exposures
COVID-19
Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board
December 06, 2022
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q3 2022 Financial Results, Corporate Updates
November 30, 2022
Via
Investor Brand Network
BiondVax announces Third Quarter 2022 Financial Results and Provides Business Update
November 30, 2022
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Confirms Inhalation Concept of NanoAb as Therapy for COVID-19
November 29, 2022
Via
Investor Brand Network
Exposures
COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Pipeline Focused on Creating Innovative Immunotherapeutic Products for Treating Underserved Infectious and Autoimmune Diseases
November 29, 2022
Via
Investor Brand Network
Exposures
COVID-19
BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy
November 29, 2022
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Director of Communications and Investor Relations Presents at LD Micro Main Event
November 22, 2022
Via
Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at the January 2023 Biotech Showcase
November 21, 2022
Via
Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Head of Technical R&D Presents Flagship NanoAbs Platform at Recent RAFT Conference
November 18, 2022
Via
Investor Brand Network
Exposures
COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Featured in The Times of Israel Article
November 17, 2022
Via
Investor Brand Network
Topics
Economy
Exposures
Supply Chain
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Congratulates Dirk Görlich on $1.4M World Laureates Association Prize in Life Sciences
November 15, 2022
Via
Investor Brand Network
BiondVax Congratulates Dirk Görlich on $1.4 million WLA Prize in Life Sciences
November 15, 2022
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Investment Research Report
November 07, 2022
Via
Investor Brand Network
Exposures
COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at RAFT 14 Conference
November 03, 2022
Via
Investor Brand Network
Exposures
COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at LD Micro Main Event XV
October 24, 2022
Via
Investor Brand Network
Aegis Capital Corp. Acted as Sole Bookrunner on a $9.8 Million Underwritten Public Offering of ADSs for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)
January 03, 2022
NEW YORK, NY / ACCESSWIRE / January 3, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $9.8 Million Underwritten Public Offering of ADSs for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV). About...
From
Aegis Capital Corp.
Via
AccessWire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.